Pulse Biosciences, Inc. (NASDAQ:PLSE) Director Buys $949,298.08 in Stock

Pulse Biosciences, Inc. (NASDAQ:PLSE) Director Robert W. Duggan acquired 55,256 shares of the firm’s stock in a transaction that occurred on Friday, December 13th. The shares were purchased at an average price of $17.18 per share, with a total value of $949,298.08. Following the acquisition, the director now owns 42,328,717 shares of the company’s stock, valued at approximately $727,207,358.06. This trade represents a 0.13 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Pulse Biosciences Stock Performance

PLSE stock traded up $0.07 during midday trading on Tuesday, hitting $19.24. 157,588 shares of the company’s stock were exchanged, compared to its average volume of 201,113. Pulse Biosciences, Inc. has a one year low of $6.59 and a one year high of $22.69. The stock’s fifty day moving average price is $17.74 and its 200-day moving average price is $16.50.

Pulse Biosciences (NASDAQ:PLSE) last released its quarterly earnings data on Wednesday, October 30th. The company reported ($0.21) earnings per share for the quarter. During the same quarter last year, the company posted ($0.19) earnings per share.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the stock. Price T Rowe Associates Inc. MD acquired a new stake in shares of Pulse Biosciences in the first quarter valued at approximately $88,000. Cetera Advisors LLC bought a new position in shares of Pulse Biosciences in the 1st quarter valued at about $109,000. Bank of New York Mellon Corp increased its position in shares of Pulse Biosciences by 23.4% in the second quarter. Bank of New York Mellon Corp now owns 50,914 shares of the company’s stock valued at $570,000 after acquiring an additional 9,639 shares during the last quarter. Rhumbline Advisers increased its position in shares of Pulse Biosciences by 6.7% in the second quarter. Rhumbline Advisers now owns 25,729 shares of the company’s stock valued at $288,000 after acquiring an additional 1,608 shares during the last quarter. Finally, Quest Partners LLC bought a new stake in Pulse Biosciences during the second quarter worth about $91,000. Institutional investors own 76.95% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, StockNews.com raised shares of Pulse Biosciences to a “sell” rating in a research report on Thursday, December 12th.

About Pulse Biosciences

Pulse Biosciences, Inc operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.